story of the week
Addition of Bevacizumab to Erlotinib as First-Line Treatment in EGFR-Mutated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Erlotinib Alone or With Bevacizumab as First-Line Therapy in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer Harbouring EGFR Mutations (JO25567): An Open-Label, Randomised, Multicentre, Phase 2 Study
Lancet Oncol 2014 Oct 01;15(11)1236-44, T Seto, T Kato, M Nishio, K Goto, S Atagi, Y Hosomi, N Yamamoto, T Hida, M Maemondo, K Nakagawa, S Nagase, I Okamoto, T Yamanaka, K Tajima, R Harada, M Fukuoka, N YamamotoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.